Last reviewed · How we verify
Isolation of multipotent cells
At a glance
| Generic name | Isolation of multipotent cells |
|---|---|
| Sponsor | I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Clinical Efficacy of Autologous Adipose Tissue Derived ADSCSs in Treatment of Osteoarthritis (OA) (PHASE1, PHASE2)
- Adipose Tissue Derived Stromal Vascular Fraction (SVF) Application in Treatment of Long Bones Nonunion (PHASE1, PHASE2)
- Analysis of the Osteogenic Potential of Multipotent Cells From Different Anatomical Regions
- Allogeneic ADSCs and Platelet-Poor Plasma Fibrin Hydrogel to Treat the Patients With Burn Wounds (ADSCs-BWs) (PHASE1, PHASE2)
- Mesenchymal Stem Cells Therapy for Treatment of Airway Remodeling in Mustard Patients (PHASE1)
- Stem Cell Educator Therapy in Type 2 Diabetes (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: